Ribavarin
PreclinicalSmall molecule
Merck & Co.Ribavarin is one of 45 small molecule programs targeting Chronic Hepatitis. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
44
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
71 competitors in Chronic Hepatitis
#DrugCompanyPhaseTrials
1Hepsera
GileadApproved
PEG-Intron
Merck & Co.Phase 3
Emtriva
GileadApproved
Jardiance
Boehringer IngelheimApproved
Opdivo
Bristol-Myers SquibbPhase 2
Pegylated Interferon Alfa
Merck & Co.Phase 3
NA Therapy
GSKPhase 3
AHB-137
AAusper Biopharma Co., Ltd.
Phase 3
Hydronidone
BBeijing Continent Pharmaceutical Co, Ltd.
Phase 3
Azvudine
HHenan Genuine Biotech Co., Ltd.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Chronic Hepatitis2 trials
Role of Heme Oxygenase in the Pathogenesis of Hepatocellular Injury in Chronic Hepatitis C Virus (HCV) Infection
Unknown status·—·N/A·NCT00842205·150 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ribavarin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company